vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and TSS, Inc. (TSSI). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $60.9M, roughly 1.4× TSS, Inc.). On growth, TSS, Inc. posted the faster year-over-year revenue change (21.8% vs 17.7%). TSS, Inc. produced more free cash flow last quarter ($15.8M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 95.8%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
IOVA vs TSSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $60.9M |
| Net Profit | — | $12.2M |
| Gross Margin | 67.4% | 17.6% |
| Operating Margin | -84.7% | 1.5% |
| Net Margin | — | 20.0% |
| Revenue YoY | 17.7% | 21.8% |
| Net Profit YoY | — | 535.7% |
| EPS (diluted) | — | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $60.9M | ||
| Q3 25 | $67.5M | $41.9M | ||
| Q2 25 | $60.0M | $44.0M | ||
| Q1 25 | $49.3M | $99.0M | ||
| Q4 24 | $73.7M | $50.0M | ||
| Q3 24 | $58.6M | $70.1M | ||
| Q2 24 | $31.1M | $12.2M | ||
| Q1 24 | $715.0K | $15.9M |
| Q4 25 | — | $12.2M | ||
| Q3 25 | $-91.3M | $-1.5M | ||
| Q2 25 | $-111.7M | $1.5M | ||
| Q1 25 | $-116.2M | $3.0M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | $-83.5M | $2.6M | ||
| Q2 24 | $-97.1M | $1.4M | ||
| Q1 24 | $-113.0M | $15.0K |
| Q4 25 | 67.4% | 17.6% | ||
| Q3 25 | 43.0% | 11.1% | ||
| Q2 25 | 5.5% | 17.8% | ||
| Q1 25 | -0.8% | 9.3% | ||
| Q4 24 | 68.7% | 14.4% | ||
| Q3 24 | 46.2% | 11.3% | ||
| Q2 24 | -0.8% | 37.3% | ||
| Q1 24 | — | 17.1% |
| Q4 25 | -84.7% | 1.5% | ||
| Q3 25 | -140.7% | -2.2% | ||
| Q2 25 | -189.8% | 5.1% | ||
| Q1 25 | -245.8% | 4.2% | ||
| Q4 24 | -117.5% | 0.0% | ||
| Q3 24 | -152.1% | 5.4% | ||
| Q2 24 | -327.6% | 14.0% | ||
| Q1 24 | -16464.6% | 1.6% |
| Q4 25 | — | 20.0% | ||
| Q3 25 | -135.3% | -3.6% | ||
| Q2 25 | -186.2% | 3.4% | ||
| Q1 25 | -235.5% | 3.0% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | -142.7% | 3.8% | ||
| Q2 24 | -312.2% | 11.5% | ||
| Q1 24 | -15800.8% | 0.1% |
| Q4 25 | — | $0.44 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | $-0.33 | $0.06 | ||
| Q1 25 | $-0.36 | $0.12 | ||
| Q4 24 | $-0.24 | $0.08 | ||
| Q3 24 | $-0.28 | $0.10 | ||
| Q2 24 | $-0.34 | $0.06 | ||
| Q1 24 | $-0.42 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $85.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $76.6M |
| Total Assets | $913.2M | $184.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $85.5M | ||
| Q3 25 | $300.8M | $70.7M | ||
| Q2 25 | $301.2M | — | ||
| Q1 25 | $359.7M | — | ||
| Q4 24 | $323.8M | $23.2M | ||
| Q3 24 | $397.5M | $46.4M | ||
| Q2 24 | $412.5M | $8.3M | ||
| Q1 24 | $356.2M | $14.4M |
| Q4 25 | $698.6M | $76.6M | ||
| Q3 25 | $702.3M | $63.4M | ||
| Q2 25 | $698.5M | $9.5M | ||
| Q1 25 | $767.9M | $9.4M | ||
| Q4 24 | $710.4M | $7.1M | ||
| Q3 24 | $773.5M | $7.7M | ||
| Q2 24 | $768.5M | $5.2M | ||
| Q1 24 | $680.0M | $3.7M |
| Q4 25 | $913.2M | $184.9M | ||
| Q3 25 | $904.9M | $165.4M | ||
| Q2 25 | $907.4M | $139.5M | ||
| Q1 25 | $966.7M | $113.5M | ||
| Q4 24 | $910.4M | $96.6M | ||
| Q3 24 | $991.1M | $67.3M | ||
| Q2 24 | $964.3M | $28.9M | ||
| Q1 24 | $869.8M | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $16.3M |
| Free Cash FlowOCF − Capex | $-61.9M | $15.8M |
| FCF MarginFCF / Revenue | -71.3% | 25.9% |
| Capex IntensityCapex / Revenue | 10.7% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $16.3M | ||
| Q3 25 | $-78.7M | $-18.4M | ||
| Q2 25 | $-67.4M | $16.3M | ||
| Q1 25 | $-103.7M | $20.6M | ||
| Q4 24 | $-73.3M | $-21.6M | ||
| Q3 24 | $-59.0M | $38.6M | ||
| Q2 24 | $-98.4M | $-4.3M | ||
| Q1 24 | $-122.3M | $2.6M |
| Q4 25 | $-61.9M | $15.8M | ||
| Q3 25 | $-89.5M | $-24.9M | ||
| Q2 25 | $-74.9M | $5.4M | ||
| Q1 25 | $-109.9M | $5.8M | ||
| Q4 24 | $-77.5M | $-28.4M | ||
| Q3 24 | $-61.3M | $38.6M | ||
| Q2 24 | $-98.9M | $-6.0M | ||
| Q1 24 | $-126.5M | $2.6M |
| Q4 25 | -71.3% | 25.9% | ||
| Q3 25 | -132.7% | -59.3% | ||
| Q2 25 | -124.9% | 12.3% | ||
| Q1 25 | -222.8% | 5.8% | ||
| Q4 24 | -105.1% | -56.7% | ||
| Q3 24 | -104.6% | 55.1% | ||
| Q2 24 | -317.9% | -49.4% | ||
| Q1 24 | -17685.3% | 16.4% |
| Q4 25 | 10.7% | 0.9% | ||
| Q3 25 | 16.1% | 15.3% | ||
| Q2 25 | 12.4% | 24.8% | ||
| Q1 25 | 12.6% | 15.0% | ||
| Q4 24 | 5.7% | 13.4% | ||
| Q3 24 | 3.9% | 0.1% | ||
| Q2 24 | 1.4% | 13.8% | ||
| Q1 24 | 583.4% | 0.2% |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 11.02× | ||
| Q1 25 | — | 6.93× | ||
| Q4 24 | — | -11.32× | ||
| Q3 24 | — | 14.60× | ||
| Q2 24 | — | -3.09× | ||
| Q1 24 | — | 176.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
TSSI
| Procurement Revenues Segment | $43.2M | 71% |
| System Integration Services Segment | $14.2M | 23% |
| Facilities Segment | $3.5M | 6% |
